Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma

Daniel Y Kim; Susan M Swetter; Linden Huhmann; Matthew P Dizon; Jacqueline M Ferguson; Thomas F Osborne; Allyson C Spence; Amina Ziad; Nathanael Fillmore; Rebecca I Hartman

doi:10.1016/j.jaad.2023.10.051

Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma

J Am Acad Dermatol. 2024 Mar;90(3):620-623. doi: 10.1016/j.jaad.2023.10.051. Epub 2023 Nov 3.

Authors

Affiliations

¹ Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
² Department of Dermatology, Stanford University Medical Center, Palo Alto, California; Dermatology Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California.
³ Massachusetts Veterans Epidemiology Research and Information Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts.
⁴ Dermatology Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California; Center for Innovation to Implementation, Veterans Affairs Palo Alto Health Care System, Menlo Park, California.
⁵ Center for Innovation to Implementation, Veterans Affairs Palo Alto Health Care System, Menlo Park, California.
⁶ Veterans Affairs Palo Alto Health Care System, Palo Alto, California; Department of Radiology, Stanford University School of Medicine, Palo Alto, California.
⁷ Department of Medical Oncology, Stanford University Medical Center, Palo Alto, California.
⁸ Harvard Medical School, Boston, Massachusetts; Massachusetts Veterans Epidemiology Research and Information Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts; Department of Medicine, Veterans Affairs Boston Healthcare System, Boston, Massachusetts; Dana Farber Cancer Institute, Boston, Massachusetts.
⁹ Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Dermatology Section, VA Integrated Service Network 1 (VISN-1), Jamaica Plain, Massachusetts. Electronic address: [email protected].

PMID: 37924953
DOI: 10.1016/j.jaad.2023.10.051

No abstract available

Keywords: BRAF; ICI; MEK; VA; adjuvant; cobimetinib; cutaneous; dabrafenib; immune checkpoint inhibitors; ipilimumab; melanoma; metastatic; nivolumab; pembrolizumab; real-world; stage III; stage IV; systemic; targeted therapies; vemurafenib; veteran.

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Humans
Immune Checkpoint Inhibitors / therapeutic use
Ipilimumab / therapeutic use
Melanoma* / drug therapy
Mitogen-Activated Protein Kinase Kinases
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins B-raf / genetics
Skin Neoplasms* / drug therapy
Veterans*

Substances

Immune Checkpoint Inhibitors
Proto-Oncogene Proteins B-raf
Ipilimumab
Protein Kinase Inhibitors
Mitogen-Activated Protein Kinase Kinases
BRAF protein, human